Should You Buy Bristol-Myers Squibb Company Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Bristol-Myers Squibb Company (BMY) scores a robust 8.5/10 on our 32-signal Quality of Company framework. At the current market price of $63.73 and a $130.2B market cap, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.
The short answer: 9 of 11 CirclFi valuation models project upside for Bristol-Myers Squibb Company (BMY) at $63.73 — the model consensus leans bullish, with a Quality Score of 8.5/10 and Value-Trap risk of 17/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Bristol-Myers Squibb Company (BMY) in 2026?
What Is the Bull Case vs the Bear Case for Bristol-Myers Squibb Company (BMY)?
| Bull case — $215.33 target (+237.9%) | Bear case — $3.70 target (-94.2%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Bristol-Myers Squibb Company's score of 8.5/10 reflects durable competitive advantages that should sustain earnings power through market cycles. | According to the CirclFi Deep Alpha Valuation Engine, the Earnings Power Value (EPV) model sees the stock as overvalued with a fair value of $3.70 (-94.2%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the stock shows multi-model upside with a median implied return of +49.4% across 9 bullish models from the current price of $63.73. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +332.1% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| According to the CirclFi Deep Alpha Valuation Engine, the Bayesian DCF model targets a fair value of $215.33 (+237.9%), anchoring the bull case with a methodology that incorporates probability-weighted cash flow scenarios. | Industry headwind: regulatory rejection risk represents a meaningful risk for Bristol-Myers Squibb Company and its Drug Manufacturers - General peers. |
| Industry tailwind: late-stage pipeline catalysts could provide meaningful support for Bristol-Myers Squibb Company's revenue and margin trajectory in the Drug Manufacturers - General space. | |
| Scale advantage: as a $130.2B large-cap company, Bristol-Myers Squibb Company benefits from economies of scale, institutional investor demand, and index inclusion that smaller competitors lack. |
How Does BMY Compare to Its Drug Manufacturers - General Peers?
Valuation data pages: GSK · AMGN · JNJ · BIIB · AZN · ABBV · PFE · MIRA · MRK · GILD
Which Other Stocks Score Like BMY on Quality?
Closest companies to BMY’s Quality of Company score of 8.5/10, across all industries.
- NWPX — NWPX Infrastructure, Inc. (QOC 8.5) · analysis
- SKYW — SkyWest, Inc. (QOC 8.5) · analysis
- ENSG — The Ensign Group, Inc. (QOC 8.5) · analysis
- ETST — Earth Science Tech, Inc. (QOC 8.5) · analysis
- PLOW — Douglas Dynamics, Inc. (QOC 8.5) · analysis
- MTG — MGIC Investment Corporation (QOC 8.5) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
So Is Bristol-Myers Squibb Company (BMY) Worth Buying in 2026?
The convergence of 8.5/10 quality, multi-model undervaluation (9/11 bullish, +49.4% median upside), and a median fair value of $95.21 vs. $63.73 current price makes Bristol-Myers Squibb Company one of the more compelling opportunities in our coverage. As always, our models provide a quantitative starting point — not a substitute for individual due diligence.
These are quantitative model outputs, not investment recommendations. Bristol-Myers Squibb Company's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About BMY Stock?
Should I buy BMY stock right now?
Based on CirclFi's multi-model analysis, 9 of 11 models see upside for BMY at $63.73. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 8.5/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Bristol-Myers Squibb Company?
Key risks include: wide model disagreement (5721% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - General companies. Always diversify and consult a financial advisor.
How does BMY compare to its competitors?
Among Drug Manufacturers - General peers, BMY holds a Quality Score of 8.5/10. Comparable companies include GSK (QOC 8.5), AMGN (QOC 8.4), JNJ (QOC 9.0). The relative ranking helps investors identify whether BMY offers better fundamental quality than alternatives in the same sector.
Is BMY a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. BMY's Quality Score of 8.5/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy BMY at?
CirclFi does not provide target buy prices or price alerts. However, our 11 active models produce fair value estimates ranging from $3.70 to $215.33. At $63.73, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for BMY.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad